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To the Editor: 
The study from Bajaj et al – evaluating the safety and efficacy of fecal microbiota transplant (FMT) as 
treatment for hepatic encephalopathy (HE)1 – raises several questions.   
A first issue concerns the omission of specific detail regarding the medical therapy being used to 
treat HE in participants at recruitment, and the implication that lactulose/ rifaximin was restarted 
after FMT in the treatment arm.  If there was greater use of medical therapy for HE in the FMT arm 
compared to standard-of-care, this difference may be an alternative explanation for the apparent 
reduced HE burden in these patients.  Furthermore, recommencement of rifaximin shortly after FMT 
would surely be inappropriate, as the broad-spectrum nature of this non-absorbable antibiotic2,3 
would intuitively minimise the chance of successful colonisation of recipients with bacterial 
communities present within the FMT.   
Another issue regards appropriate donor selection.  The authors describe using machine learning to 
select a donor with high stool relative abundance of Lachnospiraceae and Ruminococcaceae, given 
that these microbial families are found at reduced relative abundance in the stool of patients with 
HE4.  However, the data presented demonstrate that relative abundance of these two families in 
FMT-treated patients appear no different than baseline levels by day 15 post-FMT (remaining 
throughout at levels much lower than that of the donor), and Shannon diversity index was also 
statistically unchanged from baseline at this timepoint.  Given the timescale of these microbial 
changes, it seems unfeasible that the apparent improvement in PHES testing/ EncephalApp-Stroop 
and reduced HE events (all outcomes measured at day 15 post-FMT or later) was attributable to 
Lachnospiraceae and Ruminococcaceae members derived from the FMT.  Recent data demonstrate 
that sterile stool filtrates may have similar efficacy in treating recurrent Clostridium difficile infection 
as conventional FMT5, consistent with bacterially-derived proteins, gut metabolites, bacteriophages 
or other filtrate ĐoŵpoŶeŶts ďeiŶg the ŵediators of FMT’s effiĐaĐy iŶ treatiŶg this ĐoŶditioŶ, as 
opposed to intact microorganisms.   By extrapolation, for future studies in this area, a more rational 
means of donor selection may be based around not purely matching the structure of the gut 
microbiota, but to select donors with the gut microbiota functionality missing in HE.    
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